Research programme: metabolic disorder therapeutics - Energesis Pharmaceuticals

Drug Profile

Research programme: metabolic disorder therapeutics - Energesis Pharmaceuticals

Alternative Names: Brown adipose tissue stimulants - Energesis Pharmaceuticals; Brown fat stimulants - Energesis Pharmaceuticals; Brown fat-based therapeutics - Energesis Pharmaceuticals

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Energesis Pharmaceuticals
  • Developer Energesis Pharmaceuticals; Janssen Pharmaceuticals
  • Class
  • Mechanism of Action Cell division stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Metabolic disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Metabolic-disorders in USA
  • 01 May 2014 Energesis Pharmaceuticals receives Phase I SBIR grant from National Institutes of Health for Metabolic disorder therapeutics
  • 01 Jun 2012 Energesis Pharmaceuticals receives Phase II STTR grant for Metabolic disorder therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top